Effect of 3 Years of Exercise on Development of Atrial Fibrillation
This is a substudy of "Generation 100". In that study, 4000 healthy persons between 70 and 75 will be randomised do moderate intensity, high intensity or control group, with 3 years of exercise. The investigators will follow these persons and register all who develop atrial fibrillation during these 3 years, and at follow-up after ended intervention to see if there is differences in the number of persons who develop atrial fibrillation in the 3 groups.
Behavioral: High intensity exercise
Behavioral: Moderate intensity exercise
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Effect of 3 Years of Exercise on Development of Atrial Fibrillation - A "Generation 100" Substudy|
- Number of persons who develop atrial fibrillation during the 3 year intervention period [ Time Frame: 3 years ] [ Designated as safety issue: No ]People who already have the diagnosis before randomisation will not be counted.
- Number of persons who develop atrial fibrillation during the 6 years after randomisation [ Time Frame: 6 years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||December 2025|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: High intensity exercise
High intensity exercise(Borg 16) in intervals.
|Behavioral: High intensity exercise|
Experimental: Moderate intensity exercise
Moderate intensity exercise 3 times a week.
|Behavioral: Moderate intensity exercise|
Experimental: Control group
Exercise on their own. Follow current guidelines.
Advised to follow current guidelines for physical activity, but exercise on their own.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01680302
|Contact: Vegard Malmoemail@example.com|
|Norwegian University of Science and Technology||Recruiting|
|Trondheim, Norway, 7491|
|Sub-Investigator: Vegard Malmo|
|Study Chair:||Jan Paal Loennechen, PhD||St. Olavs Hospital|